Cargando…

Abstract 24 Improving Cord Blood Unit Selection and Optimizing Manufacturing of a Unique Cord Blood-Derived Product (DUOC-01)

INTRODUCTION: DUOC-01 are microglia-like cells derived from umbilical cord blood CD14-positive monocytes, which have been shown to induce remyelination in murine models of demyelination. Intrathecal DUOC-01 administration is being tested clinically in two phase I studies. First, DUOC-01 is being tes...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozamiz, April, Shoulars, Kevin, Noldner, Pamela, Shaz, Beth, Kurtzberg, Joanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446921/
http://dx.doi.org/10.1093/stcltm/szac057.024
_version_ 1784783747164405760
author Ozamiz, April
Shoulars, Kevin
Noldner, Pamela
Shaz, Beth
Kurtzberg, Joanne
author_facet Ozamiz, April
Shoulars, Kevin
Noldner, Pamela
Shaz, Beth
Kurtzberg, Joanne
author_sort Ozamiz, April
collection PubMed
description INTRODUCTION: DUOC-01 are microglia-like cells derived from umbilical cord blood CD14-positive monocytes, which have been shown to induce remyelination in murine models of demyelination. Intrathecal DUOC-01 administration is being tested clinically in two phase I studies. First, DUOC-01 is being tested as a bridging therapy for pediatric patients with inherited leukodystrophies undergoing unrelated donor cord blood transplantation. Second, DUOC-01 is being tested in a phase Ia dose escalation study in patients with primary progressive multiple sclerosis. OBJECTIVE: DUOC-01 is manufactured from an HLA-matched cryopreserved cord blood unit (CBU). The CBU is thawed and cultured for 21 days under specific conditions, and the resulting DUOC-01 is harvested and formulated with hydrocortisone for intrathecal administration. Cell dosing per patient is limited by DUOC-01 yield, which is highly variable; therefore, there is great need to increase DUOC-01 yield and optimize manufacturing for more consistency. METHODS: (1) For the identification of optimal CBU selection, units are screened using small scale DUOC-01 cultures derived from CBU bag segments, which are then scored (0-4). In order to assess the value, we performed screening followed by DUOC-01 manufacturing and correlated the screening score to the DUOC-01 yield. (2) We assessed multiple variables to optimize DUOC-01 manufacturing including media volume and temperature, fetal bovine serum (FBS) lot variability, and culture container material. RESULTS: (1) 5/13 segments scored high (defined as ≥2) while the remaining 8/13 scored low (<2). All 5 high-scored CBUs resulted in high yield (defined as ≥1.6(4) total cells/cm(2)). Of the 8 low-scored segments, 4 were low yield and 4 were high yield. (2) Comparison of different FBS lots did not show a significant change in DUOC-01 yield. Furthermore, media volume and temperature did not influence product yield. The choice of container material substantially impacted culture yields and cell viability (Figure 1). DISCUSSION: In order to increase cell yield and improve product consistency, we confirmed the value of the CBU segment screening assay and discovered the potential importance of culture container material. More experiments are needed to optimize and finalize product manufacturing.
format Online
Article
Text
id pubmed-9446921
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-94469212022-09-06 Abstract 24 Improving Cord Blood Unit Selection and Optimizing Manufacturing of a Unique Cord Blood-Derived Product (DUOC-01) Ozamiz, April Shoulars, Kevin Noldner, Pamela Shaz, Beth Kurtzberg, Joanne Stem Cells Transl Med Cord Blood Collection, Manufacturing, and Cell Engineering INTRODUCTION: DUOC-01 are microglia-like cells derived from umbilical cord blood CD14-positive monocytes, which have been shown to induce remyelination in murine models of demyelination. Intrathecal DUOC-01 administration is being tested clinically in two phase I studies. First, DUOC-01 is being tested as a bridging therapy for pediatric patients with inherited leukodystrophies undergoing unrelated donor cord blood transplantation. Second, DUOC-01 is being tested in a phase Ia dose escalation study in patients with primary progressive multiple sclerosis. OBJECTIVE: DUOC-01 is manufactured from an HLA-matched cryopreserved cord blood unit (CBU). The CBU is thawed and cultured for 21 days under specific conditions, and the resulting DUOC-01 is harvested and formulated with hydrocortisone for intrathecal administration. Cell dosing per patient is limited by DUOC-01 yield, which is highly variable; therefore, there is great need to increase DUOC-01 yield and optimize manufacturing for more consistency. METHODS: (1) For the identification of optimal CBU selection, units are screened using small scale DUOC-01 cultures derived from CBU bag segments, which are then scored (0-4). In order to assess the value, we performed screening followed by DUOC-01 manufacturing and correlated the screening score to the DUOC-01 yield. (2) We assessed multiple variables to optimize DUOC-01 manufacturing including media volume and temperature, fetal bovine serum (FBS) lot variability, and culture container material. RESULTS: (1) 5/13 segments scored high (defined as ≥2) while the remaining 8/13 scored low (<2). All 5 high-scored CBUs resulted in high yield (defined as ≥1.6(4) total cells/cm(2)). Of the 8 low-scored segments, 4 were low yield and 4 were high yield. (2) Comparison of different FBS lots did not show a significant change in DUOC-01 yield. Furthermore, media volume and temperature did not influence product yield. The choice of container material substantially impacted culture yields and cell viability (Figure 1). DISCUSSION: In order to increase cell yield and improve product consistency, we confirmed the value of the CBU segment screening assay and discovered the potential importance of culture container material. More experiments are needed to optimize and finalize product manufacturing. Oxford University Press 2022-09-06 /pmc/articles/PMC9446921/ http://dx.doi.org/10.1093/stcltm/szac057.024 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Cord Blood Collection, Manufacturing, and Cell Engineering
Ozamiz, April
Shoulars, Kevin
Noldner, Pamela
Shaz, Beth
Kurtzberg, Joanne
Abstract 24 Improving Cord Blood Unit Selection and Optimizing Manufacturing of a Unique Cord Blood-Derived Product (DUOC-01)
title Abstract 24 Improving Cord Blood Unit Selection and Optimizing Manufacturing of a Unique Cord Blood-Derived Product (DUOC-01)
title_full Abstract 24 Improving Cord Blood Unit Selection and Optimizing Manufacturing of a Unique Cord Blood-Derived Product (DUOC-01)
title_fullStr Abstract 24 Improving Cord Blood Unit Selection and Optimizing Manufacturing of a Unique Cord Blood-Derived Product (DUOC-01)
title_full_unstemmed Abstract 24 Improving Cord Blood Unit Selection and Optimizing Manufacturing of a Unique Cord Blood-Derived Product (DUOC-01)
title_short Abstract 24 Improving Cord Blood Unit Selection and Optimizing Manufacturing of a Unique Cord Blood-Derived Product (DUOC-01)
title_sort abstract 24 improving cord blood unit selection and optimizing manufacturing of a unique cord blood-derived product (duoc-01)
topic Cord Blood Collection, Manufacturing, and Cell Engineering
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446921/
http://dx.doi.org/10.1093/stcltm/szac057.024
work_keys_str_mv AT ozamizapril abstract24improvingcordbloodunitselectionandoptimizingmanufacturingofauniquecordbloodderivedproductduoc01
AT shoularskevin abstract24improvingcordbloodunitselectionandoptimizingmanufacturingofauniquecordbloodderivedproductduoc01
AT noldnerpamela abstract24improvingcordbloodunitselectionandoptimizingmanufacturingofauniquecordbloodderivedproductduoc01
AT shazbeth abstract24improvingcordbloodunitselectionandoptimizingmanufacturingofauniquecordbloodderivedproductduoc01
AT kurtzbergjoanne abstract24improvingcordbloodunitselectionandoptimizingmanufacturingofauniquecordbloodderivedproductduoc01